Sabin-IPV
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01708720 | Aug → Sep 2011 | poliomyelitis | Pauline Verdijk | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01709071 | Feb → Nov 2012 | poliomyelitis | Pauline Verdijk | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01056705 | Jul 2009 → May 2010 | poliomyelitis | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05850364 | May 2023 → Feb 2025 | poliomyelitis | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01510366 | Jan 2012 → Sep 2015 | poliomyelitis | Institute of Medical Biology, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT04576910 | Nov 2020 → Jun 2021 | poliomyelitis | Zhejiang Provincial Center for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT04053010 | Aug → Dec 2019 | — | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT03597919 | May 2018 → Sep 2019 | poliomyelitis | Centers for Disease Control and Prevention, China | Completed | No outcome recorded |
| Phase 4 | NCT03546634 | May 2018 → Jun 2019 | poliomyelitis | Centers for Disease Control and Prevention, China | Completed | No outcome recorded |
| Phase 4 | NCT04054492 | Mar 2018 → Jan 2019 | — | China National Biotec Group Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT03147560 | May → Dec 2017 | poliomyelitis | Zhejiang Provincial Center for Disease Control and Prevention | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04618783 | Jul → Dec 2019 | poliomyelitis | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04054882 Comparator | Aug 2019 → Mar 2020 | — | China National Biotec Group Company Limited | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sabin-IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04054492 ↗ |
| Known as | Inactivated Poliomyelitis Vaccine (Sabin strains) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01510366 ↗ |
| Known as | Sabin strain inactivated poliovirus vaccine | “an Sabin strain inactivated poliovirus vaccine (sIPV) manufactured by Sinovac Biotech Ltd., Beijing China” NCT04618783 ↗ |
| Known as | Sabin-strain IPV | “alternative schedules that use Sabin-strain IPV (sIPV) and bOPV” PMID 32442523 ↗ May 2020 |
| Known as | Sabin-strain-based inactivated poliovirus vaccine | “The Sabin-strain-based inactivated poliovirus vaccine (sIPV) and the diphtheria-tetanus-acellular pertussis vaccine (DTaP) have been licensed in China for many years.” PMID 35958596 ↗ Jul 20221“Sabin strain-based inactivated poliovirus vaccine (sIPV)” PMID 32747216 ↗ Jul 2020 |
| Known as | Sabin-strain-based inactivated poliovirus vaccine (vero cell) | “Immunogenicity and safety of co-administration with the Sabin-strain-based inactivated poliovirus vaccine (vero cell) and the diphtheria-tetanus-acellular pertussis vaccine in...” PMID 40969746 ↗ Sep 2025 |
| Known as | sIPV | “In a previous phase 3 clinical trial, we showed that an inactivated poliovirus vaccine derived from the Sabin strain (sIPV) can induce neutralising antibodies against currently...” PMID 37745024 ↗ Sep 20237“The Sabin-strain-based inactivated poliovirus vaccine (sIPV) and the diphtheria-tetanus-acellular pertussis vaccine (DTaP) have been licensed in China for many years.” PMID 35958596 ↗ Jul 2022 “Safety and immunogenicity of Sabin-IPV (sIPV) was evaluated in a double-blind, randomized, controlled, dose-escalation trial in the target population.” PMID 25043278 ↗ Jul 2014 “This study is designed to study the immunogenicity and safety of sIPV co-administered with other routine infant vaccines.” NCT05850364 ↗ “Sabin inactivated and bivalent oral poliovirus vaccine (sIPV, bOPV) were commonly used in China since 2016.” PMID 37283972 ↗ Mar 2023 “an Sabin strain inactivated poliovirus vaccine (sIPV) manufactured by Sinovac Biotech Ltd., Beijing China” NCT04618783 ↗ “alternative schedules that use Sabin-strain IPV (sIPV) and bOPV” PMID 32442523 ↗ May 2020 “Sabin strain-based inactivated poliovirus vaccine (sIPV)” PMID 32747216 ↗ Jul 2020 |
| Modality | Vaccine | “A Sabin strain-based inactivated poliomyelitis vaccine (Sabin-IPV) is the rational option for completely eradicating poliovirus transmission.” PMID 28419204 ↗ May 2017 |
| Route | Intramuscular | “3 x 0.5ml intramuscular injections” NCT01510366 ↗ |